Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
Heliyon May 1, 2023 Jolien K. E. Veraart, M. van Westenbrugge, J.E. van Wulfften Palthe et al. 30 citations
Introduction: Ketamine and its S-enantiomer esketamine are novel pharmacotherapeutic options for treatment resistant depression (TRD). There is growing evidence on the efficacy for other psychiatric disorders, including posttraumatic stress disorder (PTSD). It is hypothesized that psychotherapy may further potentiate the effects of (es)ketamine in psychiatric disorders. Methods: Repeated oral...